The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2021 Virtual KU Hematology and Medical Oncology Review
43:11

2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in Metastatic Sarcoma: GIST & Ripretinib, Synovial Sarcoma, Dedifferentiated Liposarcoma & CDK4/6i, Biomarker Driven Therapies

FEATURING Brian Van Tine
  • 104 views
  • July 23, 2021
  • 1
25:06

2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Survivorship Highlights: Remote Symptom Monitoring, Inpatient Care, Pharmacogenomic Studies, QoL

FEATURING Elizabeth Wulff-Burchfield
  • 7 views
  • July 23, 2021
30:04

2021 Virtual KU Hematology and Medical Oncology Review

2021 Updates in HNSCC: Expert Overview of Recent Clinical Trials

FEATURING Barbara Burtness
  • 155 views
  • July 23, 2021
  • 2
09:13

2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Updates in Head and Neck Cancers: Advanced NPC, HPV-Related Oropharynx Cancer, RAI-Refractory Thyroid Cancer

FEATURING Barbara Burtness
  • 33 views
  • July 23, 2021
18:15

2021 Virtual KU Hematology and Medical Oncology Review

KUMC Highlights on mCRC: Recent Data on Changes in the SoC

FEATURING Weijing Sun
  • 220 views
  • July 23, 2021
  • 2
06:25

2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC Metastatic Prostate Cancer Updates: 177Lu-PSMA-617 in mCRPC, Abiraterone Acetate + Prednisone +/- Local RT in De Novo mCSPC

FEATURING Saqib Abbasi
  • 30 views
  • July 22, 2021
08:08

2021 Virtual KU Hematology and Medical Oncology Review

2021 Developments in RCC & UC: Pembro for ccRCC, Sacituzumab Govitecan for mUC, Enfortumab Vedotin for Advanced UC, Bladder Sparing Treatment

FEATURING Saqib Abbasi
  • 55 views
  • July 22, 2021
15:17

2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in CML: Prognostic Scores, Treatment Goals, 1L & Beyond Therapy Options

FEATURING Abdulraheem Yacoub
  • 110 views
  • July 22, 2021
  • 1
05:01

2021 Virtual KU Hematology and Medical Oncology Review

2021 Advances in Myelofibrosis: Parsaclisib + Ruxolitinib Combinations

FEATURING Abdulraheem Yacoub
  • 160 views
  • July 22, 2021
  • 1
10:52

2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC NDMM Updates: Assessing Current Trials for Treatment, Induction Therapy, and Role of HDCT/ASCT in Clinical Practice

FEATURING Al-Ola Abdallah
  • 83 views
  • July 22, 2021
07:17

2021 Virtual KU Hematology and Medical Oncology Review

2021 KUMC Updates on Triple R/R MM: Does Ide-Cel Improve Overall Response?

FEATURING Al-Ola Abdallah
  • 8 views
  • July 22, 2021
27:42

2021 Virtual KU Hematology and Medical Oncology Review

CAR T-Cell and CRISPR in Hematologic Malignancies: Continuing Revolution of Cancer Therapeutics

FEATURING Joseph McGuirk
  • 150 views
  • July 22, 2021
  • 1
10:44

2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Highlights on TNBC: Durvalumab + Neoadjuvant Therapy in Early Stage Patients, Platinum-Based Chemo vs. Capecitabine in Residual Disease

FEATURING Qamar Khan
  • 201 views
  • July 22, 2021
08:59

2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Review of the OlympiA Trial for High-Risk EBC: Do Adjuvant PARPi Improve Outcomes?

FEATURING Qamar Khan
  • 280 views
  • July 22, 2021
  • 3
10:17

2021 Virtual KU Hematology and Medical Oncology Review

ASCO 2021 Updates on De-Escalation Strategies in BC: Talazoparib for gBRCA1/2 Operable TNBC, Neoadjuvant Trastuzumab & Pertuzumab +/- Paclitaxel for HER2+/HR− EBC

FEATURING Qamar Khan
  • 60 views
  • July 22, 2021